Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Change in Receivables (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Change in Receivables for 13 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 296.57% to $1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $756000.0, a 40.89% decrease, with the full-year FY2025 number at $756000.0, down 40.89% from a year prior.
  • Change in Receivables was $1.3 million for Q4 2025 at Niagen Bioscience, up from -$1.2 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $3.8 million in Q4 2022 to a low of -$2.7 million in Q2 2023.
  • A 5-year average of $283850.0 and a median of $326000.0 in 2021 define the central range for Change in Receivables.
  • Biggest YoY gain for Change in Receivables was 2802.31% in 2022; the steepest drop was 251.76% in 2022.
  • Niagen Bioscience's Change in Receivables stood at $130000.0 in 2021, then soared by 2802.31% to $3.8 million in 2022, then tumbled by 109.22% to -$348000.0 in 2023, then crashed by 84.48% to -$642000.0 in 2024, then surged by 296.57% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Change in Receivables are $1.3 million (Q4 2025), -$1.2 million (Q3 2025), and $2.7 million (Q2 2025).